slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,301-6,330
Pages 296
Rows per page 30
Slide type
6,301-6,330 of 8,880
13
The funnel structure implies a progression of depth and time commitment for learners.Coursera | Investor Presentation Deck | 31 slides · Coursera
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
07
The slide uses a three-column layout to categorize product offerings.Doximity | Investor Presentation Deck | 18 slides · Doximity
Pitch deck Investor relations 1 hit
05
Equillium | Investor Presentation Deck | 40 slidesEquillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the creation of 'Drug Products'.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
12
The slide highlights the commonality of the γC receptor subunit across different cytokine receptors, positioning it as a therapeutic target.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
13
The slide uses a process flow diagram to explain the scientific methodology behind the company's proprietary therapeutic platform.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
14
The slide uses a biological process diagram to illustrate the mechanism and a bar chart to demonstrate selective inhibition.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
16
This is a section divider or introductory slide for the product solution.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
17
The slide uses a four-column structure to explain the drug's mechanism, structure, preclinical results, and clinical status.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
19
The slide uses western blot data to demonstrate the mechanism of action difference between the competitor (Ruxolitinib) and the company's drug (EQ101).Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
22
The diagram uses a circular flow/flywheel-like representation to show the disease cycle.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
28
The slide uses a four-column process flow to explain the biological rationale, mechanism, preclinical validation, and development status.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
32
The diagram shows a circular process where inhibitors block IL-15 and IL-21 to prevent damage to gut epithelium.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
33
The slide uses a process-like flow to highlight 'reduce inflammation' as the key target, supported by logos of major pharma companies.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
11
The slide uses a process flow diagram to show the integration of product, technology, and data infrastructure.FinWise Bancorp | Investor Presentation Deck | 24 slides · FinWise Bancorp
Pitch deck Investor relations 1 hit
06
Uses a process flow diagram to illustrate the transition from cold to hot tumor states.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
07
The central diagram illustrates the biological mechanism of action, contrasting 'Absence of Effector T Cells' (Platinum resistant) with 'Presence of Effector T Cells' (Platinum sensitive).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
04
The slide uses a 'ribbon' layout to highlight four key pillars of the company's methodology.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
10
Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Slide 12 of the deck.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · ProductLoop · Mece Breakdown1 hit
15
The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
Includes technical definitions of selectivity index and experimental conditions for Wistar Han rats.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and define the specific clinical opportunity for each.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses three distinct chart types to demonstrate competitive advantages in potency, PK, and selectivity.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
Includes three distinct preclinical assay results: In Vitro Activity, Selectivity Index, and Brain Penetrance.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
07
Includes a biological pathway diagram and a dose-response curve showing target validation.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide presents experimental evidence (Western blot) supporting the mechanism of action for NXP800 in ARID1a-deficient cancer cells.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
The slide uses a structural biology mechanism of action (MOA) comparison to demonstrate competitive advantage.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Voice Of Customer1 hit
18
Includes a biological pathway diagram and an IC50 dose-response curve.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Voice Of Customer1 hit
20
Includes two distinct experimental setups: in vitro proliferation assays and in vivo bioluminescence imaging (BLI) tumor growth studies.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit